A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
Status:
Completed
Trial end date:
2021-10-15
Target enrollment:
Participant gender:
Summary
This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are at least 40
years old. People taking standard medicines for IPF, including antifibrotic medicines, can
continue taking them throughout the study.
The purpose of the study is to find out whether a medicine called BI 1015550 can slow down
the worsening of lung function. Participants are in the study for about 4 months. During this
time, they visit the study site about 7 times. At the beginning, they visit the study site
every 2 weeks.
After 1 month of treatment, they visit the study site every 4 weeks.
The participants are put into 2 groups by chance. 1 group gets BI 1015550. The other group
gets placebo. Placebo tablets look like BI 1015550 tablets but contain no medicine. The
participants take BI 1015550 or placebo tablets twice a day.
The participants have lung function tests at study visits. The results of the lung function
tests are compared between the BI 1015550 group and the placebo group. The doctors also
regularly check the general health of the participants.